Loading patent…
AssigneeInserm (Institut National De La Sante Et De La Recherche Medicale)
InventorsEtienne Baulieu, Beatrice Chambraud
Estimating the term…
The invention relates generally to neuroprotection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease). The invention describes AND INCLUDES a direct interaction between proteins FKBP52 and Tau. More particularly, the invention relates to a method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction comprising the following steps: a) determining the ability of a candidate compound, to modulate the interaction between a Tau polypeptide and a FKBP52 polypeptide and b) selecting positively the candidate compound that modulates said interaction. The present invention finally relates to diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction.
1-10. (canceled)
A method of treating mammalian eukaryotic cells comprising the administration to said mammalian eukaryotic cells of an effective amount of a compound which enhances the interaction between pathologic Tau and FKBP52 proteins, so as to prevent the dysfunction of Tau protein.
A method of preventing the accumulation or aggregation of Tau protein in mammalian eukaryotic cells comprising the administration to said mammalian eukaryotic cells of an effective amount of a compound which enhances the interaction between pathologic Tau and FKBP52 proteins.
A method according to claim 5 further comprising the step of selecting said compound by performing the steps of:
Dependencies are inferred from the claim text.